Ten Thousand Steps Started as a 1965 Pedometer Ad. In the Mortality Data, the Curve Flattens Closer to Seven Thousand.
Nobody picked 10,000 steps by studying people. In 1965 the Japanese company Yamasa sold a pedometer called the manpo-kei, which translates as ten thousand step meter, and the round number stuck. For decades it was repeated by fitness trackers, workplace wellness programs and doctors, largely because it was easy to remember. Starting around 2019, large cohorts began strapping accelerometers to tens of thousands of people and following them until some of them died. The results are now good enough to replace the slogan with actual numbers. They show a steep drop in mortality risk over the first few thousand steps, a flattening that arrives earlier for older adults, and a clear gap where a randomized trial should be. This article walks through what those numbers say and what they do not.
Key Takeaways: What the Step Count Evidence Actually Shows
The 10,000 steps target traces to a 1965 Japanese pedometer called the manpo-kei, sold by Yamasa, and was not derived from health outcome data. The Paluch meta-analysis in Lancet Public Health in March 2022 pooled 15 cohorts and 47,471 adults and found that, compared with a median of 3,553 steps per day, a median of 5,801 steps was associated with a hazard ratio for all-cause death of 0.60, 7,842 steps with 0.55, and 10,901 steps with 0.47. In the same analysis, mortality risk levelled off at roughly 6,000 to 8,000 steps per day for adults aged 60 and older and 8,000 to 10,000 steps for adults under 60. The Ding meta-analysis in Lancet Public Health in 2025, covering 57 studies, associated 7,000 steps per day with 47 percent lower all-cause mortality, 38 percent lower dementia risk and 37 percent lower cancer mortality compared with 2,000 steps per day. Walking pace added little once total step volume was accounted for in the Paluch, Lee and Saint-Maurice analyses. A 2007 JAMA review of 26 studies found that pedometer use raised physical activity by about 2,491 steps per day. No randomized controlled trial has tested whether increasing daily steps reduces mortality, so every mortality figure in this article is an observational association.
Where did the 10,000 steps a day target come from?
The 10,000 steps target came from a product name, not a study. In 1965 the Japanese clockmaker Yamasa launched a waist-worn pedometer called the manpo-kei, and man means ten thousand in Japanese. The device arrived in the wake of the 1964 Tokyo Olympics, when interest in fitness was high, and the number was chosen because it was round, memorable and ambitious. Later commentary sometimes credits Japanese physician Yoshiro Hatano with the figure, but the device and its name set the target long before large outcome studies existed. The 10,000 figure then spread through Japanese walking clubs, pedometer manufacturers and eventually the consumer wearables industry, where it became the default daily goal on millions of devices. The practical consequence is that a generation of men has judged its daily activity against a threshold that nobody validated. For a sedentary 55 year old who averages 3,500 steps, 10,000 can look so far away that it discourages any attempt at all, and the mortality data suggests that discouragement costs more than the missing steps would.
How many steps a day are linked to lower mortality?
In the largest pooled analyses, risk of death falls steadily as daily steps rise from about 2,500 to 3,500, and most of the reduction is captured by somewhere between 6,000 and 9,000 steps. The Paluch meta-analysis in Lancet Public Health in March 2022 is the cleanest reference because every participant wore a device rather than reporting activity from memory. It pooled 15 international cohorts, 47,471 adults and 3,013 deaths over a median follow-up of 7.1 years. The lowest quartile had a median of 3,553 steps per day. Compared with that group, people in the second quartile at a median of 5,801 steps had a hazard ratio for all-cause death of 0.60, the third quartile at 7,842 steps had 0.55, and the top quartile at 10,901 steps had 0.47. The first jump of roughly 2,250 steps was associated with a 40 percent lower risk. The next 5,100 steps together added another 13 percentage points. A separate 2023 meta-analysis in the Journal of the American College of Cardiology by Stens and colleagues, covering 12 studies and 111,309 people, found that measurable benefit began at about 2,517 steps per day and that the largest reduction in all-cause mortality sat near 8,763 steps. The shape of the curve matters more than any single number on it: it drops steeply, then bends, then flattens.
More Steps, Lower Risk, Then the Curve Bends
Hazard ratios for all-cause death by quartile of daily steps in the 2022 Lancet Public Health meta-analysis by Paluch and colleagues, which pooled 15 cohorts and 47,471 adults. The lowest quartile, with a median of 3,553 steps per day, is the reference at 1.00. Moving to the second quartile, a median of 5,801 steps, was associated with 40 percent lower risk. The third and fourth quartiles, at medians of 7,842 and 10,901 steps, added smaller increments on top. Most of the gain sits in the first few thousand steps above a sedentary baseline.
Is 7,000 steps a day enough?
For most men, particularly those over 60, 7,000 steps per day captures the large majority of the mortality benefit seen in cohort data. The most comprehensive summary to date is the Ding meta-analysis in Lancet Public Health in 2025, which pooled 57 studies and examined a range of health outcomes rather than mortality alone. Compared with 2,000 steps per day, 7,000 steps was associated with 47 percent lower all-cause mortality, 47 percent lower cardiovascular mortality, 25 percent lower incidence of cardiovascular disease, 37 percent lower cancer mortality, 38 percent lower dementia risk, 22 percent fewer depressive symptoms, 28 percent fewer falls and 14 percent lower incidence of type 2 diabetes. Moving from 7,000 to 10,000 steps added further reductions for a few outcomes, but for most outcomes the gains were small. The Ding authors suggested 7,000 steps as a realistic target that still carries most of the associated benefit. None of this makes 10,000 steps harmful. It makes 7,000 steps a defensible goal for a man who currently walks 3,000 and finds five digits demoralizing.
What 7,000 Steps Was Linked To, Outcome by Outcome
Percentage lower risk at 7,000 steps per day compared with 2,000 steps per day, from the 2025 Lancet Public Health meta-analysis by Ding and colleagues covering 57 studies. The associations are strongest for death from any cause and death from cardiovascular disease, and weakest for type 2 diabetes. These are observational associations, and people who walk more differ from people who walk less in ways no statistical model fully removes.
Do older men need fewer steps than younger men?
Yes, the mortality curve flattens at a lower step count for adults over 60 than for younger adults. In the Paluch meta-analysis, the reduction in risk levelled off at roughly 6,000 to 8,000 steps per day for adults aged 60 and older, while adults under 60 kept seeing lower risk up to roughly 8,000 to 10,000 steps. The Lee study in JAMA Internal Medicine in 2019, which followed 16,741 women with a mean age of 72 for an average of 4.3 years, found the same pattern: mortality fell as steps rose from a median of 2,718 to 4,363 per day, with a hazard ratio of 0.59 at 4,363 steps, and the curve levelled off at about 7,500 steps. A plausible explanation is that a given number of steps represents a larger share of an older person's physical capacity, so each step carries more physiological load. The Lee cohort was entirely female, which limits direct application to men, but the Paluch analysis included both sexes and the age pattern held. For a man in his sixties, 7,000 to 8,000 steps sits on the flat part of the curve. For a man in his forties, the data supports aiming a little higher.
Where Different Studies Put the Useful Range
Step counts at which major analyses located a threshold, a plateau or an optimum for all-cause mortality. Stens and colleagues in JACC in 2023 found measurable benefit starting at about 2,517 steps per day and an optimum near 8,763. Lee and colleagues found the curve levelled off near 7,500 steps in 16,741 older women. Paluch and colleagues put the plateau at 6,000 to 8,000 steps for adults over 60 and 8,000 to 10,000 for younger adults; the midpoints of those ranges are shown. The 10,000 figure is shown for comparison and did not come from any of these datasets.
Does walking faster matter more than walking more?
Once total daily steps are counted, walking pace adds little to the mortality association in most device-measured studies. The Saint-Maurice study in JAMA in March 2020 followed 4,840 US adults aged 40 and older from the National Health and Nutrition Examination Survey for a mean of 10.1 years, during which 1,165 died. Compared with 4,000 steps per day, 8,000 steps was associated with a hazard ratio for all-cause death of 0.49 and 12,000 steps with 0.35. Step intensity, measured as cadence, was not significantly associated with mortality after adjustment for total steps. The Lee and Paluch analyses reached the same conclusion. The picture is not unanimous. A 2022 UK Biobank analysis in JAMA Internal Medicine by del Pozo Cruz and colleagues, covering about 78,500 adults with wrist accelerometers, found that each additional 2,000 steps was associated with 8 to 11 percent lower risk of death, cardiovascular disease and cancer up to roughly 10,000 steps, and that a higher peak 30-minute cadence carried an association of its own. The practical reading for men is that volume comes first. Brisk walking is still useful, particularly for cardiorespiratory fitness, which predicts mortality strongly on its own, but a man who walks 8,000 slow steps is not doing worse than one who walks 5,000 fast ones.
Do you have to hit your step target every day?
No, and one large analysis found that reaching 8,000 steps on only one or two days per week was associated with most of the benefit of reaching it daily. The Inoue study in JAMA Network Open in March 2023 analysed 3,101 US adults who wore accelerometers for a week and were followed for 10 years. Compared with participants who never reached 8,000 steps in that week, those who reached it on one or two days had 14.9 percent lower all-cause mortality, and those who reached it on three to seven days had 16.5 percent lower mortality. Cardiovascular mortality followed the same pattern. The finding lines up with the separate weekend warrior literature on exercise minutes, which shows that concentrating activity into fewer days carries associations similar to spreading it out. For a man whose workdays are spent at a desk, two long walks on the weekend are not a consolation prize. They appear to count.
Hitting 8,000 Steps Twice a Week Captured Most of the Benefit
Percentage lower all-cause mortality over 10 years in 3,101 US adults from the 2023 JAMA Network Open analysis by Inoue and colleagues, compared with people who never reached 8,000 steps in a monitored week. Reaching 8,000 steps on one or two days was associated with 14.9 percent lower risk. Reaching it on three to seven days was associated with 16.5 percent lower risk. The extra days added surprisingly little on top of the first two.
Can these studies prove that walking more makes you live longer?
No, step count studies cannot prove cause and effect, because every mortality figure comes from observational cohorts rather than randomized trials. The main problem is reverse causation. Men with undiagnosed heart failure, lung disease, cancer, depression or joint problems walk less because they are already sick, and they also die sooner, which makes low step counts look more dangerous than they may be. Several cohorts tried to reduce this by excluding deaths in the first year or two of follow-up, which helps but cannot remove the problem entirely when follow-up lasts only four to ten years. Confounding by income, diet, smoking, body weight and neighbourhood walkability adds further uncertainty. What makes the association credible despite these limits is its consistency: it appears across dozens of cohorts, in multiple countries, with devices rather than questionnaires, and in a dose-response shape that fits known biology on blood pressure, insulin sensitivity and cardiorespiratory fitness. What the evidence can support is that walking more is associated with lower risk. Whether an individual man who adds 3,000 steps will gain the full 40 percent drop seen between quartiles is unknown, and is probably optimistic.
Do step goals and pedometers actually change how much men walk?
Yes, pedometer and step goal interventions reliably increase daily steps by roughly 2,000 to 2,500, at least over months. The Bravata systematic review in JAMA in 2007 analysed 26 studies with 2,767 participants and found that pedometer users increased their physical activity by about 2,491 steps per day compared with controls, alongside a 0.38 point drop in body mass index and a 3.8 mmHg drop in systolic blood pressure. Having a specific step goal was one of the strongest predictors of success. Those numbers line up neatly with the Paluch data, where the jump from the lowest to the second quartile was about 2,250 steps and carried the largest drop in risk. Roughly 2,000 steps corresponds to about 1.5 kilometres or 15 to 20 minutes of walking for most men. This is an educational review and not medical advice. Men with heart disease, chest pain on exertion, uncontrolled blood pressure or joint problems should speak with a physician before raising their activity, and anyone taking medications that affect heart rate or blood sugar should ask how a new walking routine interacts with them.
The Step Count Record on One Axis
Every strand of the step count evidence arranged as a single schematic map. Blue marks what the evidence supports, amber marks real limits that do not sink the case, slate marks findings that count against common beliefs, and dark grey marks claims the evidence does not carry. More daily steps are consistently linked to lower mortality in large device-measured cohorts, the curve flattens well below 10,000 for older adults, and no randomized trial has yet tested whether adding steps changes when people die.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+ is a coenzyme built from two nucleotides. What NAD+ is used for, what IV NAD+ studies found, and how it differs from SS-31.